Protalix BioTherapeutics, Inc. (PLX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Protalix BioTherapeutics, Inc. (PLX) closed at USD 2.61 on 2026-10-14, a change of +13.5 % over the past year, with a market capitalization of USD 217.54M.
Protalix BioTherapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 2.61 |
| 2026-10-13 | 2.75 |
| 2026-10-12 | 2.78 |
| 2026-10-09 | 2.78 |
| 2026-10-08 | 2.70 |
| 2026-10-07 | 2.71 |
| 2026-10-06 | 2.73 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Protalix BioTherapeutics, Inc. key figures
- Previous close
- USD 2.61 (2026-10-14)
- 1-year change
- +13.5 %
- Market cap
- USD 217.54M
- Enterprise value
- USD 186.09M
- P/E ratio (trailing)
- 11.74
- P/E ratio (forward)
- 4.36
- EPS (trailing)
- 0.23
- EPS (forward)
- 0.62
- PEG ratio
- n/a
- Price to book
- 3.05
- Revenue growth
- 27.1 %
- Earnings growth
- 2,241.1 %
- Dividend per share (trailing)
- 0.00
- Short ratio
- 4.16
- Employees
- 226
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Protalix BioTherapeutics, Inc. and compare it with other stocks.
Analyze PLXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Protalix BioTherapeutics, Inc. shares.